Clinical Trial Update: Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 study evaluates the safety (reactogenicity) and immunogenicity of the cervico-vaginal CN54gp140-hsp70 conjugate HIV vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• CN54gp140-hsp70 conjugate vaccine (CN54gp140-hsp70 conjugate vaccine)

Snippet

Sponsor: St George's, University of London | Conditions: HIV Infections | Phase 1 | Status: COMPLETED